Τετάρτη 10 Νοεμβρίου 2021

Drug Approval: Nivolumab plus ipilimumab for patients with MSI -high metastatic colorectal cancer previously treated with 5-fluorouracilchemotherapy

xlomafota13 shared this article with you from Inoreader

Bull Cancer. 2021 Oct 29:S0007-4551(21)00392-1. doi: 10.1016/j.bulcan.2021.08.010. Online ahead of print.

NO ABSTRACT

PMID:34756719 | DOI:10.1016/j.bulcan.2021.08.010

View on the web

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου